Actual Medicinal Product (AMP) Acamprosate 333mg gastro-resistant tablets (Mawdsley-Brooks & Company Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
Medicines suitable for use in MCAs, although use is likely to be off-label. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
- Notes
-
No special requirements for storage.
- Provenance
-
Our compatibility recommendation for Acamprosate 333mg gastro-resistant tablets is based on information from Merck Serono Ltd.
- Generic
- Acamprosate
- Formulation
- Acamprosate 333mg gastro-resistant tablets
-
Acamprosate
-
Acamprosate 333mg gastro-resistant tablets
-
Acamprosate 333mg gastro-resistant tablets (Mawdsley-Brooks & Company Ltd)
-
-